Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*,

Slides:



Advertisements
Similar presentations
David Kerr University of Oxford Oxford, UK
Advertisements

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.
A Phase III Trial Comparing FULV to FULV + Oxaliplatin in Stage II or III Carcinoma of the Colon: Results of NSABP-C-07 Norman Wolmark, MD Colorectal Cancer.
1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.
D. Haller, 1 J. Cassidy, 2 J. Tabernero, 3 J. Maroun, 4 F. de Braud, 5 T. Price, 6 E. Van Cutsem, 7 M. Hill, 8 F. Gilberg, 9 H-J. Schmoll 10 1 University.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Adjuvante therapie van het coloncarcinoom anno : is 5FU/LV nog steeds de standaard? Prof.dr. C.J.A. Punt afd. Medische Oncologie UMC St. Radboud.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.
Diabetes mellitus and the incidence and time to onset of oxaliplatin-induced peripheral sensory neuropathy in patients with colorectal cancer: A pooled.
Intergroup trial CALGB 80101
1 Stage III Colon Cancer What Works? Thierry André, MD Medical Oncology Departement, Hôpital Saint Antoine, APHP, Paris, France and University Pierre et.
Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.
ESMO/ECCO Presidential Session III
Phase III studies of Xeloda® in colorectal cancer (CRC)
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up.
Discussion abstracts Alberto Sobrero MD Ospedale San Martino Genoa, Italy.
Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC
Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.
A Report from ASCO-GI 2008 and ASCO 2007 Up-to-Date Review of the Treatment of Adjuvant Colorectal Cancer Axel Grothey, MD Professor of Oncology Mayo Clinic.
Capecitabine versus Bolus 5-FU/Leucovorin as Adjuvant Therapy for Colon Cancer: X-ACT Trial Results James Cassidy, MD Colorectal Cancer Update Think Tank.
Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.
Poster #382 XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated.
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.
Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.
*University Hospital Gasthuisberg, Leuven, Belgium
Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact.
This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.
Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB
Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD
Outcomes Following Adjuvant 5-FU based Treatment (AT) for Colon Cancer vs Impact on Recurrence Rate, Time from Recurrence to Death.
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
Xeloda for the adjuvant treatment of stage III colon cancer Chris Twelves University of Leeds and Bradford NHS Trust UK.
Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,
Best of ASCO – Colorectal & Pancreatic Cancers Best of ASCO Colorectal & Pancreatic Cancers Ali Shamseddine, MD Professor of Medicine Head of Hematology/Oncology.
0 Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer NCCTG Intergroup Phase III Trial N0147 Jocelin Huang, Daniel J Sargent,
KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.
XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
Preliminary Results from a Phase II study of FOLFIRI and Bevacizumab as First Line Treatment for Metastatic Colorectal Cancer (Abstract #3579) S. Kopetz,
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.
Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC)
Lymph Node (LN) Ratio (LNR) Based Risk Classification (RC) in Stage III Colon Cancer (CC) with Internal and External Validation: Finding from the ACCENT.
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.
Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.
Adjuvant Therapy of Colon Cancer: Where are we now ? Leonard Saltz, MD Memorial Sloan Kettering Cancer Center New York, NY.
Age > 50 Abstract Background Limited data exists regarding outcomes and AT benefit/toxicity in Y pts with stage II and III CC. We examined overall survival.
Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.
Results Abstract Analysis of Prognostic Web-based Models for Stage II and III Colon Cancer: A Population-based Validation of Numeracy and Adjuvant! Online.
A three-arm randomized phase III trial of FOLFOX4 vs FOLFOX4 + bevacizumab vs XELOX + bevacizumab in the adjuvant treatment of patients with stage III.
Cetuximab plus FOLFIRI 1 st -line in patients (pts) with metastatic colorectal cancer (mCRC): A quality of life (QoL) analysis of the CRYSTAL trial G.
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer In association.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*,
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
Jordan Berlin Co-Director, GI Oncology Program
Meta-analysis of three trials investigating 5-FU and irinotecan.
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.
2 or 3 Year DFS is an Appropriate Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with Fluoropyrimidines with or without Oxaliplatin or Irinotecan.
Presentation transcript:

Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*, M. R. Mahoney*, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey*, F. Sinicrope*, S. G. Nair, S. R. Alberts*; Mayo Clinic, Rochester, MN * ; National Surgical Adjuvant Breast and Bowel Project; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Vanderbilt University Medical Center, Nashville, TN; University of North Carolina at Chapel Hill, Chapel Hill, NC; British Columbia Cancer Agency, Vancouver, BC; University of Texas Health Science Center at San Antonio, San Antonio, TX; St. Luke's Regional Medical Center, Sioux City, IA; Mayo Clinic College of Medicine, Rochester, MN; Lehigh Valley Hospital, Allentown, PA BACKGROUND  Irinotecan (CPT-11) has demonstrated antitumor activity against metastatic colorectal cancer used alone or with 5-fluorouracil (5FU)/leucovorin (LV).  Two arms with CPT-11, 5FU, and LV (FOLFIRI) +/- Cetuximab (Cmab) were originally included in N0147. However, after CALGB (J Clin Oncol 25:3456, 2007), PETACC-3 (J Clin Oncol 27:3117, 2009), and Accord02 (Ann Oncol 20:674, 2009) showed no benefit to the 3-drug combination in adjuvant therapy, the CPT-11 arms of N0147 were discontinued.  We report the outcomes for patients given FOLFIRI +/- Cmab. METHODS  Patients with resected stage 3 colon cancer signed informed consent and were randomized to one of 6 arms including:  12 biweekly cycles of CPT mg/m2 d1 with LV 400 mg/m2, 5FU 400 mg/m2 bolus IV, then 46-hr IV 5FU 2,400 mg/m2 on d1-2 without (Arm B, FOLFIRI)  Or with Cmab (Arm E) 400 mg/m2 d1 cycle 1 then Cmab at 250 mg/m2 d1 & 8.  Primary endpoint was 3-year disease-free survival (DFS).  Secondary endpoints included overall survival (OS) and toxicity. RESULTS  146 patients (Arm B-106, Arm E-40) were enrolled.  Median follow-up on 79 patients in Arm B was 60 months and 59 months in Arm E for 37 patients.  WtKRAS (vs. Mt) status was associated with trends in improved DFS (HR=0.6 [95% CI ], p = 0.10) and OS (HR 0.7 [95% CI ], p = 0.34), in all treatment groups combined.  The addition of Cmab improved DFS and OS in the overall group and within wtKRAS pts.  Grade > 3 non-hematologic adverse effects were significantly increased in the Cmab-containing arm (46 vs 68%, p=0.02). Figure 1: Disease-free Survival – Wt-Kras (n=95) Table 1: Baseline Characteristics REFERENCES 1.Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB J Clin Oncol. Aug 2007;25(23): Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. Apr 2009;20(4): Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. Jul 2009;27(19): Supported by NIH Grant CA25224, Bristol-Myers Squibb, ImClone, Sanofi-Aventis, and Pfizer. Figure 2: Disease-free Survival – Mt-Kras (n=46) Patient CharacteristicFOLFIRI (N = 106) FOLFIRI+Cmab (N = 40) Median (range) Age (years)57 (25-82)59 (30-82) Gender Female Male 47% 53% 45% 55% Median (range) Follow-up (months) N = (3-72) N = (2-67) Tumor Characteristic FOLFIRI (N=106) FOLFIRI+Cmab (N=40) Histology High Low 23% 77% 25% 75% Lymph Node Involvement > 3 65% 35% 65% 35% T Stage T1 or T2 T3 T4 16% 70% 14% 12% 78% 10% K-ras mutation status Wild-type Mutant Missing 65% 31% 4% 65% 33% 2% Arm 3 Year Rates (95% CI) HR P-valueFOLFIRIN=6969.8%(60%-82%)0.31( )0.04 FOLFIRI + C225 N=2692.3%(83%-100%) Figure 3: Disease-free Survival – All Groups (n=146) CONCLUSIONS  Adjuvant FOLFIRI resulted in a 3-year DFS lower than that expected for FOLFOX.   Trends for improved DFS and OS with the addition of Cmab were observed in patients with resected stage III colon cancer patients, regardless of KRAS status.Arm 3 Year Rates (95% CI) HR P-valueFOLFIRIN=3356.3%(41%-76%)0.45( )0.19 FOLFIRI + C225 N=1382.5%(63%-100%) Arm 3 Year Rates (95% CI) HR P-valueFOLFIRIN= %(58%-77%)0.44( )0.04 FOLFIRI + C225 N=4086.6%(76%-98%) *C225 = Cetuximab UPDATED ABSTRACT Background: Irinotecan (CPT-11) has antitumor activity against metastatic colorectal cancer alone or with 5-fluorouracil (5FU)/leucovorin (LV). Two arms with CPT-11, 5FU, and LV (FOLFIRI) +/- Cetuximab (Cmab) were originally included in N0147. However, after CALGB (J Clin Oncol 25:3456, 2007), PETACC-3 (J Clin Oncol 27:3117, 2009), and Accord02 (Ann Oncol 20:674, 2009) showed no benefit to a CPT-11 combination in adjuvant therapy, the CPT-11 arms of N0147 were discontinued. We report the outcomes for patients given FOLFIRI and FOLFIRI+Cmab (F-Cmab). Methods: Patients with resected stage III colon cancer were randomized to one of 6 arms including 12 biweekly cycles of FOLFIRI (CPT mg/m2 d1 with LV 400 mg/m2, 5FU 400 mg/m2 bolus IV, then 46-hr IV 5FU 2,400 mg/m2 on d1,2) without or with Cmab 400 mg/m2 d1 cycle 1, then 250 mg/m2 d1, 8. Primary endpoint was 3-year disease-free survival (DFS). Secondary endpoints included overall survival (OS) and toxicity. Results: 146 evaluable patients (Arm B-106, Arm E-40) were enrolled; median follow-up was 59.6 months (range ). In pts with wtKRAS (vs mt) cancers, trends towards improved DFS (HR=0.6 [95% CI ], p = 0.10) and OS (HR 0.7 [95% CI ], p = 0.34) were observed without regard to treatment. The addition of Cmab improved DFS and OS in the overall group and within wtKRAS patients. Grade >= 3 non-hematologic adverse effects were significantly increased in the Cmab arm (46% vs. 68%, p = 0.02). Conclusion: In this small randomized comparison, trends for improved DFS and OS with the addition of Cmab to FOLFIRI were observed in patients with resected stage III colon cancer patients, regardless of KRAS status. Table 2: Toxicity – Grade 3-4 FOLFIRIFOLFIRI+Cmab Neutropenia14%10% Febrile Neutropenia2%3% Acne0%18% Nausea10%0% Diarrhea14%15% Paresthesias0%10% Infarction0%8% Overall53%68%